Products for Research Use Only
RegisterLogin

Jun12682

CAT: 0804-HY-157403-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-157403-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Jun12682 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor, with a Ki value of 37.7 nM and an EC50 value of 1.1 μM in the FlipGFP PLpro assay. Jun12682 has efficacy in hindering PLpro both deubiquitination and deISGylation, with Ki values of 63.5 and 38.5 nM, respectively. Jun12682 exhibits resistance in multiple PLpro mutant strains, and its enzymatic activity is comparable to that of the wild-type. Jun12682 can be used for the study of the SARS-CoV-2[1][2][3].
UNSPSC
12352005
Target
SARS-CoV; Virus Protease
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/jun12682.html
Purity
99.60
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC1=CC=C(C=C1C(N[C@@H](C2=CC(C3=CN(C)N=C3)=CC(C4=NN(CC)C=C4)=C2)C)=O)OCCN(C)C
Molecular Formula
C29H36N6O2
Molecular Weight
500.64
References & Citations
[1]Tan B, et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science. 2024 Mar 29;383 (6690) :1434-1440. |[2]Yang M, Kim M, Zhan P. Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice. Acta Pharm Sin B. 2024 Sep;14 (9) :4189-4192.|[3]Yang M, Kim M, Zhan P. Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice. Acta Pharm Sin B. 2024 Sep;14 (9) :4189-4192.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
GTR19261544-01Jun12682

Popular Products